Navigation Links
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Date:9/26/2008

ompliance of the COG in terms of patient randomization and stratification, overall survival data collection, and study monitoring. The Company supported the COG in this effort.

Following the satisfactory GCP inspection in April and the June CHMP meeting, the CHMP requested that the Company provide additional data analyses from the Phase 3 L-MTP-PE trial (INT-0133), in addition to responding to the remaining CMC questions. The Company provided this information in accordance with the timeline for preliminary consideration by the CHMP at its plenary meeting in September and will respond to open questions ahead of the November SAG-O and CHMP oral explanation hearings.

L-MTP-PE was granted orphan drug status in Europe in 2004. The MAA for L-MTP-PE was submitted to the EMEA and accepted for regulatory review in November 2006.

L-MTP-PE U.S. Regulatory Status

As previously announced, in the United States the Company continues to work with the COG as well as external experts and advisors to gather patient follow-up data from the Phase 3 L-MTP-PE trial and to respond to other questions in the non-approvable letter the Company received from the U.S. Food and Drug Administration (FDA). The Company expects to submit the amended New Drug Application (NDA) in the fourth quarter of 2008.

L-MTP-PE was granted orphan drug status in the United States in 2001. The NDA was submitted to FDA in October 2006 and was accepted for review in December 2006. The non-approvable letter was received in August 2007.

About Osteosarcoma

Between two and three percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, an
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
2. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
3. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
4. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
5. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
9. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
10. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 Professional ... in paediatric medicine by awarding the three best ... Formulation initiative (EuPFI) conference . The Formulating ... – 18 in Athens, Greece ... pharmacy students and professionals, from which three winners ...
(Date:8/21/2014)... , Aug. 21, 2014   Royal ... PHIA) today announced it has received 510(k) clearance ... market its precision planning application for Transcatheter Aortic-Valve ... TAVI application provides interventionalists with pre-procedural, high-precision positioning ... Philips TAVI planning application is available as part ...
(Date:8/21/2014)... JOSE, Calif. , Aug. 21, 2014  SI-BONE, ... medical device company that pioneered the use of the ... (MIS) device indicated for fusion of the sacroiliac (SI) ... ) published an update to its Lumbar Fusion Medical ... SI joint fusion procedure.  The policy states that the ...
Breaking Medicine Technology:Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... KVM Switches to be First Units to Sport New ... ... ATEN Technology, Inc., an,innovator of high-quality KVM (keyboard/video/mouse) and remote,connectivity ... the first LCD KVM switches to feature,product-protected antimicrobial nanocoating. The ...
... LA JOLLA, Calif., Sept. 10 TorreyPines,Therapeutics, Inc. ... its third,Phase I clinical trial for NGX267, in ... with schizophrenia (CIAS). The,compound, a functionally selective muscarinic ... when given orally to healthy male volunteers,once-daily for ...
Cached Medicine Technology:Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces 2Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces 3Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces 4TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia 2TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia 3
(Date:8/21/2014)... York (PRWEB) August 21, 2014 ... C.R. Bard, Inc. continue to move forward in ... Court, Southern District of West Virginia, Bernstein Liebhard ... on August 14th, the Court has established new ... requires special handling, division, storage and preservation. (In ...
(Date:8/21/2014)... Seattle, WA chiropractors Dr. Lincoln Kamell and ... Massage Center have recently welcomed two new massage ... LMP and Mike Larios, LMP have specialized training and ... have developed their expertise working in a variety of ... a clinical environment where massage is used on its ...
(Date:8/21/2014)... primary care physicians in rural communities do not ... according to Penn State medical and public health ... violence have limited resources if they seek help., ... help women," said Jennifer S. McCall-Hosenfeld, a primary ... public health sciences, Penn State College of Medicine. ...
(Date:8/21/2014)... August 21, 2014 The results of ... in The Journal of the American Medical Association (JAMA) ... cancers and reduces unnecessary recalls. Memorial Healthcare System was ... study. , “This study confirms what we already know ... cancers we want to find and, at the same ...
(Date:8/21/2014)... UK (PRWEB) August 21, 2014 The ... USD 15.6 billion in 2014 and reach USD 18.3 ... the forecast period. The drivers of such growth include ... rising obese and diabetic population, and surging ageing population. ... of state-of-the-art wound care products. Region-wise, North America leads ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 3Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 3
... 5, 2011 The new edition of America Speaks, ... demonstrates increasing public support for research and innovation to ... nearly 60% of Americans don,t believe we are making ... the U.S. has the best health care system in ...
... -- By gluing together cells from different genomes to form ... chimeric monkeys. In the report published online and ... said the monkeys, who are made up of as many ... successfully implanting these genetically mixed rhesus monkey embryos into mothers, ...
... HealthDay Reporter , THURSDAY, Jan. 5 (HealthDay News) ... annoying and painful but ultimately harmless problem -- a result ... a hangover after a night of drinking. But frequent ... known as gastroesophageal reflux disease, or GERD, and GERD is ...
... More than half of U.S. jails didn,t receive any vaccine ... flu, a new study says. Jail and prison inmates ... steady stream of new arrivals can introduce new types of ... for diseases to spread, researchers from the U.S. Centers for ...
... been linked to depression, according to UT Southwestern Medical ... It is believed to be the largest such investigation ... are associated with a cavalcade of health woes from ... published in Mayo Clinic Proceedings helps ...
... , THURSDAY, Jan. 5 (HealthDay News) -- Toddlers who ... disorders later in life, a new study indicates. Researchers ... found that depriving them of a single daily nap resulted ... reduced problem-solving abilities. "Many young children today are not ...
Cached Medicine News:Health News:Majority of Americans say research and development are key to building US economy 2Health News:Scientists Create First Monkeys With Mixed Genomes 2Health News:Chronic Heartburn a Growing Problem in U.S. 2Health News:Chronic Heartburn a Growing Problem in U.S. 3Health News:Many Jails Got No Flu Shots During H1N1 Outbreak: CDC 2Health News:Low vitamin D levels linked to depression, UT Southwestern psychiatrists report 2Health News:Missed Naps Could Put Toddlers at Risk for Mood Disorders 2
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 100-1,000 microliter range....
... Pipettor is the #1 Pipettor for ... comfort, and reliability. Continuously adjustable. Features ... sub-micrometer. Easy interchangeable ejector buttons to ... Adjustable rapid pipet tip ejector with ...
... adjustable, air-displacement pipette with a patented multifunctional ... of the Pipetman family, sharing many of ... We also added a number of features ... models cover the full range of volumes ...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
Medicine Products: